MODL-22. DEVELOPING A REAL-TIME PERSONALIZED DRUG TESTING PLATFORM FOR PEDIATRIC CNS CANCERS

INTRODUCTION: The relatively small size of biopsied CNS tumors has presented a historical challenge for real-time drug screens. Moreover, in vivo assessment of drug response does not often benefit patients with aggressive gliomas given the relatively long time (>8 months) of tumor engraftment in...

Descripción completa

Detalles Bibliográficos
Autores principales: Laternser, Sandra, Cosentino, Chiara Cianciolo, Przystal, Justyna M, Dettwiler, Susanne, Rushing, Elisabeth Jane, Gerber, Nicolas U, Stücklin, Ana Guerreiro, Prasad, Rachna, Grotzer, Michael, Krayenbühl, Niklaus, Müller, Sabine, Nazarian, Javad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Preclinical Models/Experimental Therapy/Drug Discovery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715439/
http://dx.doi.org/10.1093/neuonc/noaa222.595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715439/
http://dx.doi.org/10.1093/neuonc/noaa222.595

Ejemplares similares